Pembrolizumab approved for use in any cancer with a high tumor mutational burden

Share This Post

July 2021: The US Food and Medication Administration (FDA) has expanded the indications for pembrolizumab (Keytruda), an immunotherapy drug, to encompass any cancer with a high mutational burden (TMB-H). The new authorisation is for adults and children with advanced TMB-H solid tumours that are continuing developing after prior treatment and for which no other therapeutic alternatives are available.

TMB (tumour mutational burden) is a measurement of the amount of gene mutations (changes) within cancer cells that can be evaluated using a lab test. Cells with a high number of gene mutations (a high TMB) are more likely to be identified as aberrant and attacked by the body’s immune system.

An immune checkpoint inhibitor, such as Keytruda, is a type of medication. It works by assisting the immune system in recognising and attacking cancer cells.

Keytruda has previously been licenced to treat a variety of malignancies, including lung, head and neck, stomach, liver, kidney, bladder, and skin cancers, as well as lymphoma in some cases.

Keytruda was originally approved for all advanced solid cancers with various gene alterations, including high levels of microsatellite instability (MSI-H) and mismatch repair deficiency (dMMR). MSI-H or dMMR cancer cells have problems repairing DNA damage. As a result, they may appear to be extremely different from regular cells, making them more noticeable to the immune system.

The latest FDA approval is based on a clinical experiment in which TMB was detected in patients’ tumours. TMB-H malignancies were found in 102 (13%) of the 790 patients screened. Small cell lung cancer, cervical cancer, endometrial cancer, anal cancer, and vulvar cancer were the most prevalent TMB-H malignancies in the study. During treatment with this medicine, 29 percent of the 102 patients with TMB-H tumours reacted (shrank or vanished). The average time to receive a response was 30 months, with half of the responses taking at least two years.

Keytruda was authorised for the new indication under the FDA’s expedited approval and priority review processes, which allow medications to be approved faster for critical conditions. After receiving fast approval, the drug’s manufacturer must submit further clinical data to establish the drug’s benefit. Priority review indicates that the FDA aims to make a decision within six months rather than the normal ten.

Keytruda is administered as an infusion into a vein every 3 to 6 weeks.

Fatigue, fever, cough, shortness of breath, nausea, itchy skin, rash, decreased appetite, constipation, muscular or joint pain, and diarrhoea are the most typical side effects of this medication. When the medicine leads the immune system to target normal cells in the body, less common but more dangerous adverse effects can develop. This can cause major complications in the lungs, colon, hormone-producing glands, liver, skin, and other organs.

Merck & Co. manufactures Keytruda.

Take second opinion on cancer treatment

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form